Improving Cancer Outcomes Through International Collaboration in Academic Cancer Treatment Trials

Saitama Medical University, Saitama, Saitama, Japan
Journal of Clinical Oncology (Impact Factor: 18.43). 09/2009; 27(30):5109-14. DOI: 10.1200/JCO.2009.22.5771
Source: PubMed


The need for international collaboration in cancer clinical trials has grown stronger as we have made progress both in cancer treatment and screening. We sought to identify those efforts already underway which facilitate such collaboration, as well as barriers to greater collaboration.
We reviewed the collective experiences of many cooperative groups, governmental organizations, nongovernmental organizations, and academic investigators in their work to build international collaboration in cancer clinical trials across multiple disease sites.
More than a decade of work has led to effective global harmonization for many of the elements critical to cancer clinical trials. Many barriers remain, but effective international collaboration in academic cancer treatment trials should become the norm, rather than the exception.
Our ability to strengthen international collaborations will result in maximization of our resources and patients, permitting us to change practice by establishing more effective therapeutic strategies. Regulatory, logistical, and financial hurdles, however, often hamper the conduct of joint trials. We must work together as a global community to overcome these barriers so that we may continue to improve cancer treatment for patients around the world.

Download full-text


Available from: Richard S Kaplan,
  • Source
    • "The new QA center(s) will need to be mindful of these variations and work with other global QA offices in an attempt to harmonize QA efforts for these international trials while maintaining consistency in clinical trial patient treatments. The quality assurance centers have considerable experience in international collaboration in both group and industry sponsored clinical trials, therefore building upon this experience will be important moving forward as international participation becomes imbedded in the daily work scope of the quality assurance centers (Trimble et al., 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The National Cancer Institute (NCI) clinical cooperative groups have been instrumental over the past 50 years in developing clinical trials and evidence-based clinical trial processes for improvements in patient care. The cooperative groups are undergoing a transformation process to launch, conduct, and publish clinical trials more rapidly. Institutional participation in clinical trials can be made more efficient and include the expansion of relationships with international partners. This paper reviews the current processes that are in use in radiation therapy trials and the importance of maintaining effective credentialing strategies to assure the quality of the outcomes of clinical trials. The paper offers strategies to streamline and harmonize credentialing tools and processes moving forward as the NCI undergoes transformative change in the conduct of clinical trials.
    Frontiers in Oncology 12/2012; 2:198. DOI:10.3389/fonc.2012.00198

  • Journal of Clinical Oncology 11/2009; 28(2):187-9. DOI:10.1200/JCO.2009.25.8608 · 18.43 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In Japan, it is quite rare for an investigator to submit an investigational new drug application to initiate a clinical trial and obtain approval of a drug on the basis of clinical trial results. This means that development of new therapies is currently driven almost entirely by pharmaceutical companies as opposed to independent investigators. Here, we provide our perspective on the reasons for this situation and advocate investigator-initiated cancer drug development as a means of increasing access to better therapies for Japanese cancer patients.
    Nature Reviews Clinical Oncology 03/2010; 7(3):127-8. DOI:10.1038/nrclinonc.2010.13 · 14.18 Impact Factor
Show more